9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.
PierFranco Conte(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Roberto D’Amico(University of Modena and Reggio Emilia), Giovanna Cavazzini(University of Padua), Sara Balduzzi(Dutch Cancer Society), Giancarlo Bisagni, C. Taverniti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Anna Turletti(Ospedale Martini), Francesco Giotta(Istituto Tumori Bari), Elisa Anselmi(Azienda Unità Sanitaria Locale Piacenza), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), Vittorio Gebbia(La Maddalena), Elisa Picardo(Ospedale Sant'Anna), Michele Aieta(Centro di Riferimento Oncologico della Basilicata), Daniela Rubino(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo)
Cited by 36
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879